The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
aged more than 6 months.
malignant B cell surface expression CD19 molecules.
the KPS score over 80 points, and survival time is more than 3 months.
greater Hgb 80 g/L.
accompanied with other active diseases, the treatment is difficult to correct.
bacteria, fungus, or virus infection, unable to control.
people living with HIV.
active HBV and HCV infection.